Puma Biotechnology (PBYI) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed PepGen (PEPG) over the past year, gaining 44.2% versus a loss of 32.0%. Puma Biotechnology is the larger company by market cap ($364.5 million vs $356.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBYI | PEPG |
|---|---|---|
| Share price | $7.05 | $3.78 |
| Market cap | $364.47M | $356.31M |
| 1-day change | -0.98% | -3.82% |
| YTD return | +18.49% | -41.94% |
| 1-year return | +44.17% | -32.01% |
| 5-year return | +118.27% | — |
| P/E ratio (TTM) | 15.33 | — |
| Forward P/E | 20.14 | — |
| EPS (TTM) | $0.46 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $228.37M | — |
| Revenue growth (YoY) | -0.91% | — |
| Net income (latest FY) | $31.11M | $-89.66M |
| Gross margin | 74.53% | — |
| Operating margin | 16.33% | — |
| Net margin | 13.62% | — |
| 52-week high | $11.50 | $7.80 |
| 52-week low | $4.84 | $1.31 |
| Distance from 52-week high | -38.70% | -51.54% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +263.76% |
| Average volume | 387.40K | 3.26M |
| Shares outstanding | 51.70M | 94.26M |
| Employees | 179 | 53 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed PEPG by 76.2 percentage points over the past year.
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
PBYI vs PEPG FAQ
Which is bigger, Puma Biotechnology or PepGen?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $364.47M compared with $356.31M for PepGen (PEPG).
Which stock has performed better over the past year, PBYI or PEPG?
PBYI returned +44.17% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Puma Biotechnology and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.